
    
      This is an open label, parallel-group, single dose, Phase 1 study to evaluate the PK profile,
      safety, and tolerability of a single oral 450 mg dose of vadadustat in subjects with hepatic
      impairment relative to control subjects with normal hepatic function. The study will enroll
      up to 24 subjects in 3 groups of 8 subjects at 2 study sites. Blood samples for vadadustat PK
      and its metabolites will be collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24,
      36, 48, 60, and 72 hours post-dose.
    
  